Form 4: VolitionRX Director Timothy Still Receives 1.4 Million Restricted Stock Units

Director Timothy Still receives 1.4 million restricted stock units from VolitionRX, with vesting conditions tied to time and stock price performance.

Summary

• Timothy Still, a director at VolitionRX Ltd, received a total of 1,400,000 restricted stock units (RSUs) on November 6, 2024.
• 400,000 RSUs vest in three installments on November 6, 2025, 2026, and 2027.
• 1,000,000 RSUs vest in two equal installments upon achieving stock price targets of $2.50 and $5.00 per share for 30 consecutive trading days before November 6, 2027, but no earlier than November 6, 2025, followed by a six-month time-based vesting period.
• Vesting of the 1,000,000 RSUs will be accelerated if VolitionRX undergoes a Change of Control at a purchase price exceeding $2.50 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The granting of RSUs is a standard practice, and the vesting conditions provide some alignment with shareholder interests. However, there are no immediate positive or negative implications for the company's financial performance.

Positives

• The vesting of a portion of the RSUs is tied to achieving specific stock price targets, which could incentivize the director to work towards increasing shareholder value.
• The change of control clause could make the company more attractive to potential acquirers.

Risks

• The stock price targets may not be achieved, resulting in the non-vesting of a significant portion of the RSUs.
• The time-based vesting schedule could result in the director leaving the company before the RSUs fully vest.

Future Outlook

The vesting of the RSUs is contingent upon continued service and, for a portion, the achievement of specific stock price targets, aligning the director's interests with those of the shareholders.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. The specific terms of the grant, such as the vesting schedule and performance targets, are tailored to the company's specific circumstances and goals.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize equity-based compensation to align executive incentives with shareholder value.
• The vesting schedules and performance targets are generally comparable to industry norms, with the specific details varying based on company size, stage of development, and strategic objectives.

Stakeholder Impact

• Shareholders may view the RSU grants positively as they align the director's interests with increasing the company's stock price.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates